Julia Pineda, MD
Endocrinology, Diabetes & Metabolism · Washington, DCNPI 1720150279
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,350 of the $6,033 with a category attached, or 72.1%. AbbVie accounts for 84.1% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $4,510 and has fallen 99.6% since, to $20 in 2025.
Across 70 payments — averaging $86.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Boehringer Ingelheim$171
- Merck$134
- AstraZeneca$110
- IBSA Pharma Inc.$89
- Lilly USA, LLC$85
- plus $374 from 12 others
Across 11 payments — averaging $2096.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$17K
- Bavarian Nordic A/s$6K
What the payments were for
- Speaking & faculty fees$4,35072%
- Travel & lodging$4067%
- Food & beverage$1,25421%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 17 | $5,072 |
| Boehringer Ingelheim | 7 | $171 |
| Merck | 11 | $134 |
| AstraZeneca | 6 | $110 |
| IBSA Pharma Inc. | 5 | $89 |
| Lilly USA, LLC | 5 | $85 |
| Amarin Pharma, Inc. | 4 | $61 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $61 |
| Antares Pharma, Inc. | 1 | $45 |
| Corcept Therapeutics | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Novo Nordisk | 1 | $25 |
| Abbott | 1 | $23 |
| Pfizer | 1 | $23 |
| Amgen | 1 | $19 |
| Mannkind Corporation | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Synthroid$4,784
How this compares
$6,033 in reported general payments places this provider in the 70th percentile of 44 endocrinology, diabetes & metabolism providers in District of Columbia.
See all endocrinology, diabetes & metabolism providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 21 | $46,452 |
| JardianceEmpagliflozin | 12 | $20,444 |
| JanuviaSitagliptin Phosphate | 15 | $16,414 |
| EliquisApixaban | 12 | $13,480 |
| SynthroidLevothyroxine Sodium | 32 | $3,333 |
| Rosuvastatin Calcium | 104 | $2,031 |
| Candesartan Cilexetil | 22 | $1,682 |
| Levothyroxine Sodium | 99 | $1,140 |
| Ezetimibe | 20 | $1,115 |
| FenofibrateFenofibrate Nanocrystallized | 22 | $846 |
| Metformin Hcl ErMetformin Hcl | 83 | $668 |
| Pravastatin Sodium | 26 | $593 |
| Metoprolol Succinate | 40 | $582 |
| Famotidine | 24 | $501 |
| Atorvastatin Calcium | 32 | $497 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $25 | $46,45221 claims |
| Boehringer IngelheimJardiance | $171 | $20,44412 claims |
| MerckJanuvia | $134 | $16,41415 claims |
| PfizerEliquis | $23 | $13,48012 claims |
| AbbVieSynthroid | $5,072 | $3,33332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 44 endocrinology, diabetes & metabolism providers in District of Columbia.
Other endocrinology, diabetes & metabolism in Washington
- Natasa Janicic-KahricWashington$121K
- Diala El-MaoucheWashington$99K
- Abbas MotazediWashington$31K
- Meeta SharmaWashington$25K
- Joseph VerbalisWashington$24K
- Mark SklarWashington$14K
- Sabyasachi SenWashington$12K
- Rui LuWashington$12K
- Qudsia HussainWashington$9K
- Jerold ShareWashington$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.